IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+2.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$903M
AUM Growth
+$903M
(-20%)
Cap. Flow
-$189M
Cap. Flow
% of AUM
-20.9%
Top 10 Holdings %
Top 10 Hldgs %
48.7%
Holding
109
New
26
Increased
18
Reduced
25
Closed
31
Top Buys
| 1 |
Elevance Health
ELV
|
$28.3M |
| 2 |
Novartis
NVS
|
$27.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$22.6M |
| 4 |
Baxter International
BAX
|
$17.1M |
| 5 |
Ascendis Pharma
ASND
|
$15.6M |
Top Sells
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Eli Lilly
LLY
|
$29.3M |
| 4 |
Intuitive Surgical
ISRG
|
$20.9M |
| 5 |
CVS Health
CVS
|
$20.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Fate Therapeutics
FATE
$115M
| $553K | 0.06% |
700,000
+100,000
| +17% | +$79K |
|
77
Arcellx
ACLX
$3.87B
| – | – |
-100,000
| Closed | -$7.67M |
|
78
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-420,000
| Closed | -$13.4M |
|
79
AstraZeneca
AZN
$254B
| – | – |
-225,000
| Closed | -$14.7M |
|
80
Bruker
BRKR
$4.45B
| – | – |
-100,000
| Closed | -$5.86M |
|
|
81
Cardinal Health
CAH
$35.8B
| – | – |
-250,000
| Closed | -$29.6M |
|
|
CMPS
82
Compass Pathways
CMPS
$443M
| – | – |
-200,000
| Closed | -$756K |
|
|
83
Centene
CNC
$14.6B
| – | – |
-500,000
| Closed | -$30.3M |
|
84
Cooper Companies
COO
$13.2B
| – | – |
-100,000
| Closed | -$9.19M |
|
85
Quest Diagnostics
DGX
$19.9B
| – | – |
-130,000
| Closed | -$19.6M |
|
86
Exact Sciences
EXAS
$9.23B
| – | – |
-150,000
| Closed | -$8.43M |
|
87
Humana
HUM
$37.2B
| – | – |
-40,000
| Closed | -$10.1M |
|
88
Illumina
ILMN
$15.2B
| – | – |
-40,000
| Closed | -$5.35M |
|
|
89
Intuitive Surgical
ISRG
$162B
| – | – |
-40,000
| Closed | -$20.9M |
|
90
Janux Therapeutics
JANX
$1.37B
| – | – |
-200,000
| Closed | -$10.7M |
|
91
Keros Therapeutics
KROS
$640M
| – | – |
-450,000
| Closed | -$7.12M |
|
|
92
Eli Lilly
LLY
$659B
| – | – |
-38,000
| Closed | -$29.3M |
|
93
Merck
MRK
$212B
| – | – |
-200,000
| Closed | -$19.9M |
|
94
Pliant Therapeutics
PLRX
$102M
| – | – |
-300,000
| Closed | -$3.95M |
|
95
Insulet
PODD
$24B
| – | – |
-20,000
| Closed | -$5.22M |
|
96
QuidelOrtho
QDEL
$1.87B
| – | – |
-150,000
| Closed | -$6.68M |
|
97
Avidity Biosciences
RNA
$6B
| – | – |
0
| – | – |
|
98
Rhythm Pharmaceuticals
RYTM
$6.89B
| – | – |
-150,000
| Closed | -$8.4M |
|
|
SLN
99
Silence Therapeutics
SLN
$233M
| – | – |
-200,000
| Closed | -$1.38M |
|
100
STAAR Surgical
STAA
$1.36B
| – | – |
-100,000
| Closed | -$2.43M |
|